An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective.
作者信息
Patel Dhiren
机构信息
VA Boston Healthcare System, Boston, MA, USA.
出版信息
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):3-6. doi: 10.1111/jcpt.13227.
Abstract
摘要
相似文献
1
An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective.从药剂师角度看每周一次的胰高血糖素样肽-1（GLP-1）受体激动剂概述。
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):3-6. doi: 10.1111/jcpt.13227.
2
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者的心血管风险降低：这是一类药物的作用吗？
Curr Cardiol Rep. 2018 Sep 26;20(11):113. doi: 10.1007/s11886-018-1051-2.
3
Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.比较用于2型糖尿病的每周一次胰高血糖素样肽-1（GLP-1）受体激动剂，未发现明显的优胜者。
BMJ. 2015 Dec 9;351:h6702. doi: 10.1136/bmj.h6702.
4
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.每周一次司美格鲁肽与其他 GLP-1 受体激动剂在 2 型糖尿病中的成本效益比较：系统文献回顾。
Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):221-233. doi: 10.1080/14737167.2021.1860022. Epub 2021 Jan 12.
5
Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.2型糖尿病患者使用每周一次胰高血糖素样肽-1受体激动剂的心血管安全性结局
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):61-72. doi: 10.1111/jcpt.13226.
6
Once-weekly glucagon-like peptide 1 receptor agonists.每周一次的胰高血糖素样肽-1受体激动剂
J Pak Med Assoc. 2015 Jul;65(7):796-8.
7
Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.每周一次的胰高血糖素样肽-1受体激动剂对2型糖尿病患者的血糖及非血糖疗效
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):28-42. doi: 10.1111/jcpt.13224.
8
Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?司美格鲁肽用于2型糖尿病——它是最佳的胰高血糖素样肽1受体激动剂（GLP-1R激动剂）吗？
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):371-377. doi: 10.1080/17425255.2018.1441286. Epub 2018 Feb 23.
9
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.正在开发中的每周一次胰高血糖素样肽-1 激动剂治疗成人 2 型糖尿病的临床疗效和安全性。
Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379.
10
Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.胰高血糖素样肽-1 受体激动剂与心血管事件：类别效应与个体模式。
Trends Endocrinol Metab. 2018 Apr;29(4):238-248. doi: 10.1016/j.tem.2018.01.011. Epub 2018 Feb 17.
本文引用的文献
1
Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.2型糖尿病患者使用每周一次胰高血糖素样肽-1受体激动剂的心血管安全性结局
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):61-72. doi: 10.1111/jcpt.13226.
2
A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.2型糖尿病中胰高血糖素样肽-1受体激动剂的综述：聚焦于每周一次给药制剂的作用机制
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):17-27. doi: 10.1111/jcpt.13230.
3
Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.每周一次的胰高血糖素样肽-1受体激动剂对2型糖尿病患者的血糖及非血糖疗效
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):28-42. doi: 10.1111/jcpt.13224.
4
Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.采用每周一次注射 GLP-1 受体激动剂治疗管理 2 型糖尿病的多方面特性。
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):7-16. doi: 10.1111/jcpt.13229.
5
Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.GLP-1 受体激动剂每周一次给药治疗 2 型糖尿病的安全性和耐受性。
J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):43-60. doi: 10.1111/jcpt.13225.
6
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
7
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2019 年更新版：《2018 年美国糖尿病协会（ADA）与欧洲糖尿病研究协会（EASD）关于 2 型糖尿病患者高血糖管理的共识报告》。
Diabetes Care. 2020 Feb;43(2):487-493. doi: 10.2337/dci19-0066. Epub 2019 Dec 19.
8
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.度拉糖肽与 2 型糖尿病患者的心血管结局（REWIND）：一项双盲、随机、安慰剂对照试验。
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
9
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法 - 2019执行摘要的共识声明。
Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535.
10
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2018 年美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）共识报告：2 型糖尿病患者高血糖管理。
Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4.
Zotero 插件